Stock 4BMY BRISTOL-MYERS SQUIBB COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Bristol-Myers Squibb Company Borsa Italiana

Equities

4BMY

US1101221083

Real-time Estimate Tradegate
Other stock markets
 21:01:58 21/06/2024 BST 		5-day change 1st Jan Change
39.17 EUR +3.18% Intraday chart for Bristol-Myers Squibb Company -1.20% -18.19%
09:14pm Bristol-Myers Squibb's Colorectal Cancer Therapy Receives FDA Approval MT
07:27pm US FDA approves Bristol Myers' colorectal cancer therapy RE

Evolution of the average Target Price on Bristol-Myers Squibb Company

Price target over the last 5 years

History of analyst recommendation changes

89da718f1757a7.zZgsQYWnV7_klsBURa2rPJXr3O-04-vPIYMdBTUCaYA.r6x7BtOUPe6G2Y4bPJ6fWcGShof9lNuFRutncwdzH-qJ83U3xu87xpLEgQ~ebb2a0574f696014845e43ca1dc4cb72

Analyst Recommendations on Bristol-Myers Squibb Company

HSBC Adjusts Price Target on Bristol-Myers Squibb to $45 From $50 MT
ANALYST RECOMMENDATIONS : Tesla, Snap, Alphabet, Microsoft, Anglo American... Our Logo
Goldman Sachs Cuts Bristol-Myers Squibb's Price Target to $56 From $60 MT
Deutsche Bank Adjusts Price Target on Bristol-Myers Squibb to $53 From $55, Keeps Hold Rating MT
Leerink Partners Cuts Price Target on Bristol-Myers Squibb to $47 From $51 MT
UBS Cuts Bristol-Myers Squibb Price Target to $47 From $52, Maintains Neutral Rating MT
Barclays Adjusts Price Target on Bristol-Myers Squibb to $43 From $51 MT
JPMorgan Adjusts Bristol-Myers Squibb's Price Target to $60 From $65 MT
Morgan Stanley Adjusts Price Target on Bristol-Myers Squibb Company to $37 From $40 MT
Truist Cuts Price Target on Bristol-Myers Squibb to $64 From $68, Keeps Buy Rating MT
BMO Capital Adjusts Price Target on Bristol-Myers Squibb Company to $48 From $55 MT
Jefferies Adjusts Bristol-Myers Squibb Price Target to $54 From $56, Keeps Hold Rating MT
Cantor Fitzgerald Adjusts Price Target on Bristol-Myers Squibb to $45 From $52, Maintains Neutral Rating MT
Cantor Fitzgerald Adjusts Bristol-Myers Squibb's Price Target to $52 From $55, Maintains Neutral Rating MT
Wells Fargo Adjusts Bristol-Myers Squibb's Price Target to $52 From $51, Keeps Equalweight Rating MT
Wolfe Research Adjusts Price Target on Bristol-Myers Squibb Company to $55 From $57, Outperform Rating Kept MT
Wolfe Research Adjusts Price Target on Bristol-Myers Squibb to $55 From $57, Maintains Outperform Rating MT
Jefferies Cuts Bristol-Myers Squibb's Price Target to $56 From $58 MT
Morgan Stanley Trims Price Target on Bristol-Myers Squibb to $40 From $41, Keeps Underweight Rating MT
Societe Generale Downgrades Bristol-Myers Squibb to Hold From Buy, Cuts Price Target to $51 From $85 MT
Wells Fargo Adjusts Price Target on Bristol-Myers Squibb to $51 From $58, Maintains Equalweight Rating MT
Redburn Downgrades Bristol-Myers Squibb to Neutral From Buy, Adjusts Price Target to $54 From $77 MT
ANALYST RECOMMENDATIONS : Chevron, McDonald's, Palantir, Sainsbury, Tesla... Our Logo
Morgan Stanley Trims Price Target on Bristol-Myers Squibb to $41 From $42, Incorporates Mirati Transaction Into Model; Underweight Kept MT
UBS Cuts Bristol-Myers Squibb Price Target to $52 From $57, Maintains Neutral Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.04 USD
Average target price
53.19 USD
Spread / Average Target
+29.62%
High Price Target
75 USD
Spread / Highest target
+82.75%
Low Price Target
37 USD
Spread / Lowest Target
-9.84%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Bristol-Myers Squibb Company

HSBC
Goldman Sachs
Deutsche Bank Securities
Leerink Partners
UBS
Barclays
JPMorgan Chase
Morgan Stanley
Truist Securities
BMO Capital
Jefferies & Co.
Cantor Fitzgerald
Wells Fargo Securities
Wolfe Research
Societe Generale
Redburn
BofA Securities
Daiwa Securities
Berenberg Bank
William Blair & Co.
TD Cowen
Credit Suisse
Atlantic Equities
Guggenheim
Raymond James
Citigroup
Argus

Ratings for Bristol-Myers Squibb Company

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. BMY Stock
  4. 4BMY Stock
  5. Consensus Bristol-Myers Squibb Company